Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP866169.RAIl0vG-UgMEhdufXTuUjL1Qj4GaJVt5TecZGDEVCF6i8130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP866169.RAIl0vG-UgMEhdufXTuUjL1Qj4GaJVt5TecZGDEVCF6i8130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP866169.RAIl0vG-UgMEhdufXTuUjL1Qj4GaJVt5TecZGDEVCF6i8130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP866169.RAIl0vG-UgMEhdufXTuUjL1Qj4GaJVt5TecZGDEVCF6i8130_provenance.
- NP866169.RAIl0vG-UgMEhdufXTuUjL1Qj4GaJVt5TecZGDEVCF6i8130_assertion description "[Findings from the human epidermal growth factor receptor 2 (HER2) -positive National Surgical Adjuvant Breast and Bowel Project (NSABP) B31 trial suggested that MYC/HER2 coamplification (> 5.0 copies/nucleus) was associated with additional benefit from adjuvant trastuzumab in patients with early-stage breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP866169.RAIl0vG-UgMEhdufXTuUjL1Qj4GaJVt5TecZGDEVCF6i8130_provenance.
- NP866169.RAIl0vG-UgMEhdufXTuUjL1Qj4GaJVt5TecZGDEVCF6i8130_assertion evidence source_evidence_literature NP866169.RAIl0vG-UgMEhdufXTuUjL1Qj4GaJVt5TecZGDEVCF6i8130_provenance.
- NP866169.RAIl0vG-UgMEhdufXTuUjL1Qj4GaJVt5TecZGDEVCF6i8130_assertion SIO_000772 21245420 NP866169.RAIl0vG-UgMEhdufXTuUjL1Qj4GaJVt5TecZGDEVCF6i8130_provenance.
- NP866169.RAIl0vG-UgMEhdufXTuUjL1Qj4GaJVt5TecZGDEVCF6i8130_assertion wasDerivedFrom befree-2016 NP866169.RAIl0vG-UgMEhdufXTuUjL1Qj4GaJVt5TecZGDEVCF6i8130_provenance.
- NP866169.RAIl0vG-UgMEhdufXTuUjL1Qj4GaJVt5TecZGDEVCF6i8130_assertion wasGeneratedBy ECO_0000203 NP866169.RAIl0vG-UgMEhdufXTuUjL1Qj4GaJVt5TecZGDEVCF6i8130_provenance.
- befree-2016 importedOn "2016-02-19" NP866169.RAIl0vG-UgMEhdufXTuUjL1Qj4GaJVt5TecZGDEVCF6i8130_provenance.